Pharmacokinetics and Pharmacodynamics Study of Alogliptin in Healthy Korean Participants

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple-Dose Study of the Pharmacokinetics and Pharmacodynamics of Alogliptin 12.5 mg, 25 mg and 50 mg in Healthy Korean Subjects

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01391663

Enrollment

Registered

2011-07-12

Start date

2011-07-31

Completion date

2011-09-30

Last updated

2013-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pharmacokinetics and Pharmacodynamics

Keywords

Drug Therapy

Brief summary

The purpose of this study is to assess the Pharmacokinetics and Pharmacodynamics of alogliptin after a single or multiple administrations, once daily (QD), of oral alogliptin in healthy Korean subjects.

Detailed description

Alogliptin is a selective, orally available inhibitor of dipeptidyl peptidase-4 being developed by Takeda Global Research & Development Center, Inc. as a treatment for type 2 diabetes mellitus. Inhibition of dipeptidyl peptidase-4 (DPP-4) prolongs the action of 2 important incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). These hormones are responsible for increasing insulin synthesis, regulating β-cell proliferation, inhibiting gastric emptying and inhibiting glucagon secretion. Evaluations of alogliptin and its clinical efficacy have been conducted in multiple countries including the United States and Japan. As development of alogliptin expands to other countries, additional studies are needed to bridge between the data previously acquired. The main objective of this study is to assess the pharmacokinetics and pharmacodynamics of alogliptin in healthy Korean participants.

Interventions

DRUGAlogliptin

Alogliptin 12.5 mg, tablets, orally, once daily for up to 7 days.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements. 2. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures. 3. The participant is a healthy adult male or female participant of Korean descent. 4. The participant is aged 18 to 55 years, inclusive, at the time of informed consent and first study medication dose. 5. The participant has a body mass index (BMI) between 18.0 and 26.0 kg/m2, inclusive at Screening. 6. A male participant who is non-sterilized and sexually active with a female partner of childbearing potential agrees to use adequate contraception from signing of informed consent throughout the duration of the study and for 12 weeks after last the dose. 7. A female participant of childbearing potential who is sexually active with a non-sterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study and for 30 days after the last dose of study drug.

Exclusion criteria

1. The participant has received any investigational compound within 30 days prior to Screening. 2. The participant has received alogliptin in a previous clinical study or as a therapeutic agent. 3. The participant is an immediate family member, study site employee, or in a dependant relationship with a study site employee who is involved in the conduct of this study (e.g., spouse, parent, child, sibling) or may consent under duress. 4. The participant has history of uncontrolled, clinically significant manifestations of metabolic (including diabetes mellitus, hypercholesterolemia, or dyslipidemia), endocrine, hematologic, pulmonary, cardiovascular, gastrointestinal, neurological, rheumatologic, skin and subcutaneous tissue disorders, infectious, hepatic, renal, urologic, immunologic, psychiatric or mood disorders (including any past history of suicide attempt), or a history of lactose intolerance, which may impact the ability of the participant to participate or potentially confound the study results. 5. Participant has a known hypersensitivity to any component of the formulation of alogliptin. 6. The participant has a positive urine drug result for drugs of abuse or alcohol at Screening or Check-in (Day -1). 7. The participant has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 1 year prior to the Screening visit or is unwilling to agree to abstain from alcohol and drugs throughout the study. 8. Participant has taken any excluded medication, supplements, or food products listed in the Excluded Medications and Dietary Products table. 9. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 30 days after participating in this study; or intending to donate ova during such time period. 10. If male, the participant intends to donate sperm during the course of this study or for 12 weeks after the last dose. 11. Participant has evidence of current cardiovascular, central nervous system, hepatic, hematopoietic disease, renal dysfunction, metabolic or endocrine dysfunction, serious allergy, asthma hypoxemia, hypertension, seizures, or allergic skin rash. There is any finding in the participant's medical history, physical examination, or safety laboratory tests giving reasonable suspicion of a disease that would contraindicate taking alogliptin, or a similar drug in the same class, or that might interfere with the conduct of the study. This includes, but is not limited to, peptic ulcer disease, seizure disorders, and cardiac arrhythmias. 12. Participant has current or recent (within 6 months) gastrointestinal disease that would be expected to influence the absorption of drugs (i.e., a history of malabsorption, esophageal reflux, peptic ulcer disease, erosive esophagitis frequent \[more than once per week\] occurrence of heartburn, or any surgical intervention \[e.g., cholecystectomy\]). 13. Participant has a history of cancer, except basal cell carcinoma which has been in remission for at least 5 years prior to Day 1. 14. Participant has a positive test result for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV), or a known history of human immunodeficiency virus infection at the Screening visit. 15. Participant has used nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patch or nicotine gum) within 28 days prior to Check-in Day -1. Cotinine test is positive at Screening or Check-in (Day -1). 16. The participant has poor peripheral venous access. 17. Participant has donated or lost 450 mL or more of his or her blood volume (including plasmapheresis), or had a transfusion of any blood product within 30 days prior to Day 1. 18. Participant has a Screening or Check-in (Day -1) abnormal (clinically significant) electrocardiogram (ECG). Entry of any participant with an abnormal (not clinically significant) ECG must be approved, and documented by signature by the principal investigator. 19. Participant has abnormal Screening or Day -1 laboratory values that suggest a clinically significant underlying disease or participant with the following lab abnormalities: alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \>2x the upper limits of normal. 20. Participant has a hemoglobin value \<12 g/dL at Screening only. 21. Participant has a systolic blood pressure ≥140 mm Hg or has a diastolic blood pressure ≥90 mm Hg at Screening or Check-in (Day -1). 22. Participant has a serum creatinine level \>1.5 mg/dL at Screening only.

Design outcomes

Primary

Measure	Time frame	Description
Cmax: Maximum Observed Plasma Concentration Pharmacokinetic Parameter	Day 1-4, Day 10	Maximum observed plasma concentration (Cmax) is the peak plasma concentration after administrations of a single dose and multiple doses of the study drug
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) Pharmacokinetic Parameter	Day 1-4, Day 10.	Time to reach the maximum plasma concentration (Tmax) after administrations of a single dose and multiple doses of the study drug
AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity Pharmacokinetic Parameter	Day 1-4	Area under the plasma concentration-time curve from time 0 to infinity after administration of a single dose of the study drug.
AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Pharmacokinetic Parameter.	Day 1-4, Day 10.	Area under the curve from 0 to 24 hours after administrations of a single dose and multiple doses of the study drug.
Terminal Phase Elimination Half-life (T1/2) Pharmacokinetic Parameter	Day 1-4	Time required for half of the drug to be eliminated from the plasma after administration of a single dose of the study drug.
Oral Clearance (CL/F) Pharmacokinetic Parameter	Day 1-4	CL/F is apparent clearance of the drug from the plasma after administration of a single dose of the study drug.

Countries

South Korea

Participant flow

Recruitment details

Participants took part in the study at a single investigative site in South Korea from 25 July 2011 to 02 September 2011.

Pre-assignment details

Healthy Korean participants were enrolled in either alogliptin 12.5 mg, 25 mg or 50 mg once-daily (QD) treatment groups.

Participants by arm

Arm	Count
Alogliptin 12.5 mg QD Alogliptin 12.5 mg, tablets, orally, once daily for up to 7 days.	12
Alogliptin 25 mg QD Alogliptin 25 mg, tablets, orally, once daily for up to 7 days.	12
Alogliptin 50 mg QD Alogliptin 25 mg, tablets, orally, two tablets taken once daily for up to 7 days.	12
Placebo Placebo tablets, orally, two tablets taken once daily for up to 7 days.	12
Total	48

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003
Overall Study	Withdrawal by Subject	0	0	1	0

Baseline characteristics

Characteristic	Alogliptin 12.5 mg QD	Alogliptin 25 mg QD	Alogliptin 50 mg QD	Placebo	Total
Age Continuous	26.6 Years STANDARD_DEVIATION 5.05	23.5 Years STANDARD_DEVIATION 2.75	25.3 Years STANDARD_DEVIATION 7.88	25.8 Years STANDARD_DEVIATION 2.17	25.3 Years STANDARD_DEVIATION 4.97
Body Mass Index (BMI)	22.17 kg/m2 STANDARD_DEVIATION 1.35	21.67 kg/m2 STANDARD_DEVIATION 2.31	21.53 kg/m2 STANDARD_DEVIATION 2.41	21.00 kg/m2 STANDARD_DEVIATION 1.525	21.59 kg/m2 STANDARD_DEVIATION 1.94
Height	171.7 cm STANDARD_DEVIATION 9.05	170.3 cm STANDARD_DEVIATION 8.52	171.2 cm STANDARD_DEVIATION 8.62	168.9 cm STANDARD_DEVIATION 8.11	170.5 cm STANDARD_DEVIATION 8.37
Race/Ethnicity, Customized Korean	12 participants	12 participants	12 participants	12 participants	48 participants
Race/Ethnicity, Customized Other	0 participants	0 participants	0 participants	0 participants	0 participants
Sex: Female, Male Female	4 Participants	3 Participants	3 Participants	3 Participants	13 Participants
Sex: Female, Male Male	8 Participants	9 Participants	9 Participants	9 Participants	35 Participants
Weight	65.33 kg STANDARD_DEVIATION 8.76	63.37 kg STANDARD_DEVIATION 10.49	62.84 kg STANDARD_DEVIATION 9.78	60.85 kg STANDARD_DEVIATION 8.891	63.10 kg STANDARD_DEVIATION 9.34

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk
deaths Total, all-cause mortality	— / —	— / —	— / —	— / —
other Total, other adverse events	2 / 12	2 / 12	4 / 12	3 / 12
serious Total, serious adverse events	0 / 12	0 / 12	0 / 12	0 / 12

Outcome results

Primary

AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Pharmacokinetic Parameter.

Area under the curve from 0 to 24 hours after administrations of a single dose and multiple doses of the study drug.

Time frame: Day 1-4, Day 10.